Feixiong Cheng

InstitutionCase Western Reserve University
AddressCleveland
Ohio
United States
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 12 Covid-19 publications, with a maximum of 2 publications in July 2020 and Spetember 2020
    All Publications
    Bar chart showing 87 publications over 12 distinct years, with a maximum of 11 publications in 2016
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Hou Y, Zhou Y, Gack MU, Lathia JD, Kallianpur A, Mehra R, Chan TA, Jung JU, Jehi L, Eng C, Cheng F. Multimodal single-cell omics analysis identifies epithelium-immune cell interactions and immune vulnerability associated with sex differences in COVID-19. Signal Transduct Target Ther. 2021 07 30; 6(1):292. PMID: 34330889.
      Citations: 2     Translation:HumansCellsCTClinical Trials
    2. Zhou Y, Xu J, Hou Y, Leverenz JB, Kallianpur A, Mehra R, Liu Y, Yu H, Pieper AA, Jehi L, Cheng F. Network medicine links SARS-CoV-2/COVID-19 infection to brain microvascular injury and neuroinflammation in dementia-like cognitive impairment. Alzheimers Res Ther. 2021 06 09; 13(1):110. PMID: 34108016.
      Citations: 10     Fields:    Translation:HumansCells
    3. Martin WR, Cheng F. A rational design of a multi-epitope vaccine against SARS-CoV-2 which accounts for the glycan shield of the spike glycoprotein. J Biomol Struct Dyn. 2021 Mar 10; 1-15. PMID: 33715598.
      Citations: 6     Fields:    
    4. Shen J, Hou Y, Zhou Y, Mehra R, Jehi L, Cheng F. The Epidemiological and Mechanistic Understanding of the Neurological Manifestations of COVID-19: A Comprehensive Meta-Analysis and a Network Medicine Observation. Front Neurosci. 2021; 15:606926. PMID: 33732102.
      Citations: 2     
    5. Zhou Y, Hou Y, Shen J, Mehra R, Kallianpur A, Culver DA, Gack MU, Farha S, Zein J, Comhair S, Fiocchi C, Stappenbeck T, Chan T, Eng C, Jung JU, Jehi L, Erzurum S, Cheng F. A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19. PLoS Biol. 2020 11; 18(11):e3000970. PMID: 33156843.
      Citations: 46     Fields:    Translation:HumansCellsPHPublic Health
    6. Martin WR, Cheng F. Repurposing of FDA-Approved Toremifene to Treat COVID-19 by Blocking the Spike Glycoprotein and NSP14 of SARS-CoV-2. J Proteome Res. 2020 11 06; 19(11):4670-4677. PMID: 32907334.
      Citations: 20     Fields:    Translation:HumansCellsPHPublic Health
    7. Zhou Y, Wang F, Tang J, Nussinov R, Cheng F. Artificial intelligence in COVID-19 drug repurposing. Lancet Digit Health. 2020 12; 2(12):e667-e676. PMID: 32984792.
      Citations: 83     Translation:Humans
    8. Chung MK, Karnik S, Saef J, Bergmann C, Bergmann C, Barnard J, Lederman MM, Tilton J, Cheng F, Harding CV, Young JB, Mehta N, Cameron SJ, McCrae KR, Schmaier AH, Smith JD, Kalra A, Gebreselassie SK, Thomas G, Hawkins ES, Svensson LG. SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy. EBioMedicine. 2020 Aug; 58:102907. PMID: 32771682.
      Citations: 42     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    9. Zeng X, Song X, Ma T, Pan X, Zhou Y, Hou Y, Zhang Z, Li K, Karypis G, Cheng F. Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning. J Proteome Res. 2020 11 06; 19(11):4624-4636. PMID: 32654489.
      Citations: 39     Fields:    Translation:HumansCellsPHPublic Health
    10. Hou Y, Zhao J, Martin W, Kallianpur A, Chung MK, Jehi L, Sharifi N, Erzurum S, Eng C, Cheng F. New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis. BMC Med. 2020 07 15; 18(1):216. PMID: 32664879.
      Citations: 102     Fields:    Translation:HumansCellsPHPublic Health
    11. Cheng F, Rao S, Mehra R. COVID-19 treatment: Combining anti-inflammatory and antiviral therapeutics using a network-based approach. Cleve Clin J Med. 2020 Jun 30. PMID: 32606050.
      Citations: 13     Fields:    
    12. Zhou Y, Hou Y, Shen J, Huang Y, Martin W, Cheng F. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020; 6:14. PMID: 32194980.
      Citations: 557     
    Cheng's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (215)
    Explore
    _
    Co-Authors (65)
    Explore
    _
    Similar People (60)
    Explore
    _